The GLP-1 Pill Era Has Arrived: The Same Weight-Loss Medicine, Now as a Daily Tablet

For nearly a decade, the most transformative medicines in modern metabolic health came with a catch: a needle. The GLP-1 class behind Ozempic, Wegovy and Zepbound rewrote the treatment of type 2 diabetes and obesity - but every one of them was a weekly injection that had to be kept cold. That is now changing, fast. On June 15, 2026, The Lancet published results for a new once-daily GLP-1 pill, just weeks after the first such pill reached U.S. pharmacy shelves. The era of swallowing - rather than injecting - these drugs has begun.

Here is exactly what was announced, how the pills compare to the shots, and why a simple tablet may matter even more than the injections that came before it.

1. What Just Happened: A Pill That Performs Like the Shots

The new data come from SOLSTICE, a multicentre, phase 2b, randomised, placebo-controlled trial of elecoglipron - an oral, small-molecule GLP-1 receptor agonist developed by AstraZeneca. Researchers enrolled 406 adults with type 2 diabetes across nine countries and followed them for 26 weeks. The pill is taken once daily, with no food or fluid restrictions.

The headline numbers were strong:

• Blood sugar: up to 89.6% of participants reached an HbA1c under 7% - the standard treatment target - compared with just 24.9% in the placebo group.
• Weight: up to 72.3% achieved at least a 5% reduction in body weight, versus 20.2% on placebo.
• Magnitude: the highest-dose group lost about 10.5% of their body weight over 26 weeks.

The safety and tolerability profile was, in the researchers' words, consistent with the broader GLP-1 class at a similar stage of development. SOLSTICE is a mid-stage (phase 2b) study, and on the strength of these results elecoglipron is advancing into phase 3. The data were also presented at the American Diabetes Association's 2026 Scientific Sessions in New Orleans.

2. Why a Pill Is Such a Big Deal

The injectable GLP-1s already work extraordinarily well, so why is a tablet cause for excitement? Because the format - not just the molecule - is what decides how many people a medicine can actually reach.

In practice that translates into three advantages: access (no needles or refrigeration, so the medicine travels easily to clinics, rural areas, and lower-income countries), scale and cost (chemical synthesis can meet demand that has repeatedly outstripped injectable supply), and simplicity (a daily tablet is, for many people, the difference between starting treatment and never starting at all).

3. The First One Is Already on Pharmacy Shelves

Elecoglipron is the latest entrant, but it is not the first across the line. That distinction belongs to orforglipron, sold by Eli Lilly under the brand name Foundayo. On April 1, 2026, the U.S. FDA approved Foundayo for chronic weight management in adults with obesity, or who are overweight with a weight-related condition - making it the first GLP-1 pill that can be taken at any time of day with no restrictions on food or water. (An earlier oral option, the semaglutide pill, must be taken on an empty stomach with limited water and a 30-minute wait - a real-world hurdle orforglipron removes.)

Its diabetes data are equally compelling. In the head-to-head phase 3 ACHIEVE-3 trial, published in The Lancet in February 2026, orforglipron was tested directly against oral semaglutide in adults with type 2 diabetes:

Lilly has said it plans to file Foundayo for the treatment of type 2 diabetes - not just weight management - with the FDA by the end of this quarter. In its obesity trial program, the highest dose drove roughly 12.4% average weight loss.

4. Pill vs. Injection: How They Stack Up

The injectables still hold advantages - the most powerful, tirzepatide, can drive larger weight loss, and weekly dosing means less to remember day to day. The point of the pills is not that they beat the shots on every metric, but that they bring most of the benefit in a form almost anyone can use, store, and afford.

5. The Bigger Picture: Scaling a Blockbuster to the World

GLP-1 medicines have been one of the great public-health stories of the decade - shown not only to control blood sugar and reduce weight, but in major trials to lower cardiovascular risk. The limiting factor has never really been whether they work; it has been making enough of them, keeping them cold, and getting people comfortable with a weekly shot. A cheap, stable, once-daily pill attacks all three constraints at once. With one pill already approved and a second posting strong trial data weeks later, the field is moving from a single breakthrough to a genuine category - and that is when a medicine starts to reach the many, not the few.

What to Watch Next

• Phase 3 for elecoglipron - SOLSTICE is mid-stage; larger, longer trials will confirm how the once-daily pill performs at scale.
• Foundayo for diabetes - Lilly's planned FDA filing this quarter would extend the first anytime GLP-1 pill from weight management to type 2 diabetes.
• Price and coverage - the real test of the access promise is what these tablets cost patients and how broadly insurers and health systems cover them.
• Long-term durability - how well the weight and blood-sugar benefits hold over years, as more real-world data accumulate.

Sources

• The Lancet: Elecoglipron in adults with type 2 diabetes (SOLSTICE), phase 2b trial
• ScienceDaily: New GLP-1 diabetes pill delivers major weight loss and blood sugar control · Healthline: AstraZeneca's new oral GLP-1 led to 10.5% weight loss
• AstraZeneca: Elecoglipron moves to phase III programme
• Eli Lilly: FDA approves Foundayo (orforglipron), the only GLP-1 pill that can be taken any time of day · Orforglipron beats oral semaglutide head-to-head (ACHIEVE-3, The Lancet)

Curated by Jerry Cards - jerrycards.com. We research the week's most consequential tech, science, and health news so you don't have to. More at jerrycards.com/news.